Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Genovis AB's Debt-to-Equity or its related term are showing as below:
FRA:5GV'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.12 Max: 0.42
Current: 0.24
During the past 13 years, the highest Debt-to-Equity Ratio of Genovis AB was 0.42. The lowest was 0.01. And the median was 0.12.
FRA:5GV's Debt-to-Equity is ranked worse than 59.19% of 958
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:5GV: 0.24
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Genovis AB Debt-to-Equity Related Terms
Genovis AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Genovis AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5GV vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Genovis AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genovis AB Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genovis AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Genovis AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genovis AB (FRA:5GV) has a Debt-to-Equity of 0.00 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Genovis AB and its competitors. Over the past decade, Genovis AB's Debt-to-Equity has ranged from 0.01 to 0.42. According to the industry distribution chart, Genovis AB ranks #567 out of 958 companies in the Biotechnology industry, placing it in the top 59.2%.
Is Genovis AB's Debt-to-Equity too high?
Genovis AB's current Debt-to-Equity is 0.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.42. Based on the distribution chart, Genovis AB ranks #567 out of 958 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genovis AB has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genovis AB's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovis AB ranks #567 out of 958 companies for Debt-to-Equity. This places Genovis AB in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Historically, Genovis AB's own Debt-to-Equity has ranged from 0.01 to 0.42 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Genovis AB and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genovis AB's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovis AB stock overvalued right now?
Based on GuruFocus' analysis, Genovis AB (FRA:5GV) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.30, compared to a current price of €1.74 — trading 24.5% below its estimated fair value. The current Debt-to-Equity is 0.00. Genovis AB's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Genovis AB (FRA:5GV), the current Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genovis AB (FRA:5GV) Overvalued in 2026?
Based on GuruFocus' analysis, Genovis AB stock appears to be undervalued.
The current stock price of €1.74 is trading 24.5% below its estimated GF Value™ of €2.30.
GuruFocus considers Genovis AB to be Modestly Undervalued.
Key valuation signals for FRA:5GV:
Debt-to-Equity: 0.00
GF Value™: €2.30 vs. price of €1.74 (24.5% below fair value)
No single metric tells the full story. See the FRA:5GV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
94GF Score
Get the complete analysis for FRA:5GV
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5GV has been successfully added to your 
